SCHEMBL14940262

SCHEMBL14940262

O=C(OC1CCCCC1)C(O)(c1cccs1)C1CCCC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 15/20 0.64
CHRM2 P08172 14/20 0.64
CHRM1 P11229 11/20 0.64
CHRM4 P08173 3/20 0.60
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CHRM5 P08912 2/20 0.44
HRH1 P35367 2/20 0.44
KCNH2 Q12809 2/20 0.44
HTR2B P41595 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP19A1 P11511 1/20 0.43
TSPO P30536 1/20 0.41
ADRA1A P35348 1/20 0.41
OPRK1 P41145 1/20 0.41
PDE3A Q14432 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2596419 0.87 CHRM3 (0.56) CHRM3CHRM2CHRM1CHRM4CYP3A4
SCHEMBL1235445 0.86 CHRM3 (0.65) CHRM3CHRM2CHRM1CHRM4CYP3A4
SCHEMBL7140053 0.86 CHRM3 (0.60) CHRM3CHRM2CHRM1CHRM4CYP2D6
SCHEMBL7147345 0.86 CHRM3 (0.60) CHRM3CHRM2CHRM1CHRM4CYP2D6
SCHEMBL7140049 0.86 CHRM3 (0.60) CHRM3CHRM2CHRM1CHRM4CYP2D6
Bromide SCHEMBL7151353 0.85 CHRM3 (0.61) CHRM3CHRM2CHRM1CHRM4CYP2D6
SCHEMBL2596407 0.85 CHRM3 (0.57) CHRM3CHRM2CHRM1CHRM4CHRM5
SCHEMBL1234853 0.85 CHRM3 (0.63) CHRM3CHRM2CHRM1CHRM4CYP3A4
SCHEMBL13716300 0.84 CHRM3 (0.68) CHRM3CHRM2CHRM1CHRM4CYP2D6
SCHEMBL7145504 0.84 CHRM3 (0.68) CHRM3CHRM2CHRM1CHRM4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776426-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES Almirall, S.A. (ES) 2014-09-17 EP claimed
EP-2776425-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES Almirall, S.A. (ES) 2014-09-17 EP claimed
WO-2013068554-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ALMIRALL, S.A. (ES) 2013-05-16 WO claimed
WO-2013068552-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ALMIRALL, S.A. (ES) 2013-05-16 WO claimed
EP-2776426-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES Almirall, S.A. (ES) 2014-09-17 EP disclosed
EP-2776425-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES Almirall, S.A. (ES) 2014-09-17 EP disclosed
WO-2013068554-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ALMIRALL, S.A. (ES) 2013-05-16 WO disclosed
WO-2013068552-A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES ALMIRALL, S.A. (ES) 2013-05-16 WO disclosed